C4 Therapeutics, Inc.
NASDAQ:CCCC
5.51 (USD) • At close November 12, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Assets: | ||||||
| Current Assets: | ||||||
| Cash & Cash Equivalents
| 126.59 | 29.754 | 76.124 | 181.727 | 90.549 | 36.311 |
| Short Term Investments
| 127.091 | 246.399 | 233.155 | 189.962 | 0 | 0 |
| Cash and Short Term Investments
| 253.681 | 337.115 | 309.279 | 371.689 | 90.549 | 36.311 |
| Net Receivables
| 11.799 | 1.473 | 5.716 | 4.484 | 4.623 | 86.438 |
| Inventory
| 0 | -60.962 | 0 | 0 | 0 | 0 |
| Other Current Assets
| 5.709 | 9.931 | 10.694 | 4.836 | 1.595 | 0.781 |
| Total Current Assets
| 271.189 | 287.557 | 325.689 | 381.009 | 96.767 | 123.53 |
| Non-Current Assets: | ||||||
| Property, Plant & Equipment, Net
| 71.088 | 77.516 | 35.053 | 16.552 | 18.916 | 20.384 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill and Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments
| 31.451 | 60.962 | 142.2 | 2.577 | 2.577 | 2.577 |
| Tax Assets
| 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 2.723 | 4.805 | 3.823 | 0 | 0 | 0 |
| Total Non-Current Assets
| 105.262 | 143.283 | 181.076 | 19.129 | 21.493 | 22.961 |
| Total Assets
| 376.451 | 430.84 | 506.765 | 400.138 | 118.26 | 146.491 |
| Liabilities & Equity: | ||||||
| Current Liabilities: | ||||||
| Account Payables
| 1.446 | 1.172 | 4.506 | 5.683 | 5.385 | 1.154 |
| Short Term Debt
| 5.219 | 6.987 | 1.334 | 1.042 | 0.88 | 0.734 |
| Tax Payables
| 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue
| 15.471 | 33.513 | 31.8 | 27.603 | 20.705 | 19.109 |
| Other Current Liabilities
| 19.184 | 1.702 | 9.1 | 3.841 | 1.286 | 1.798 |
| Total Current Liabilities
| 42.766 | 44.546 | 51.246 | 43.852 | 33.641 | 23.949 |
| Non-Current Liabilities: | ||||||
| Long Term Debt
| 65.757 | 80.165 | 41.545 | 21.878 | 12.869 | 13.748 |
| Deferred Revenue Non-Current
| 21.814 | 16.895 | 24.368 | 53.617 | 72.718 | 77.549 |
| Deferred Tax Liabilities Non-Current
| -21.814 | 9.195 | 10.768 | 10.052 | 0 | -13.748 |
| Other Non-Current Liabilities
| 21.814 | -9.195 | -10.768 | -10.052 | 110.995 | 124.743 |
| Total Non-Current Liabilities
| 87.571 | 97.06 | 65.913 | 75.495 | 196.582 | 202.292 |
| Total Liabilities
| 130.337 | 141.606 | 117.159 | 119.347 | 230.223 | 226.241 |
| Equity: | ||||||
| Preferred Stock
| 0 | 0 | 0 | 400.138 | 110.995 | 110.995 |
| Common Stock
| 0.006 | 0.005 | 0.005 | 0.004 | 0.001 | 0.001 |
| Retained Earnings
| -528.383 | -395.89 | -267.715 | -183.823 | -117.488 | -83.389 |
| Accumulated Other Comprehensive Income/Loss
| -0.127 | -4.137 | -0.775 | 0.013 | -0.001 | -2.499 |
| Other Total Stockholders Equity
| 774.618 | 689.256 | 658.091 | 64.459 | -105.47 | -104.858 |
| Total Shareholders Equity
| 246.114 | 289.234 | 389.606 | 280.791 | -111.963 | -79.75 |
| Total Equity
| 246.114 | 289.234 | 389.606 | 280.791 | -111.963 | -79.75 |
| Total Liabilities & Shareholders Equity
| 376.451 | 430.84 | 506.765 | 400.138 | 118.26 | 146.491 |